uniQure N.V.

QURE XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

1.7B

Short interest (May 15)

16.3%

Net Short (Jun 03 ): -0.3%

Borrow Fee

0.27%

↑ 0.7%

Available Shares

↑ 21.0%

Price Chart

Company Overview

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001590560

Asset Type: CS

Market Data

Market Cap: $1,687,685,898

Employees: 221

Status: Active

Short Interest

Current Borrow Fee 0.27%

Range: 0.27% - 0.27%

Available Shares 3M

Range: 2.5M - 2.5M

Recent Changes

Fee Change: ↓ 18.5%

Available Change: ↓ 3.9%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime